Table 3.
Summary of frontline prospective trials in HIV-associated aggressive lymphomas
| Regimen | n | Trial design | Subtype | Follow-up | CR | PFS/FFS | OS | Reference |
|---|---|---|---|---|---|---|---|---|
| EPOCH | 39 | Phase II | DLBCL 79% BL 18% | 53 months | 74% | 92% | 60% | [31] |
| CDE | 55 | Phase II |
DLBCL 78% BL 22% |
24 months | 45% | 38% | 45% | [32] |
| CHOP | 72 | Phase II |
DLBCL 61% BL 11% HG NOS: 24% |
47 months | 63% | N/A | 26,1 months | [33] |
| CHOP | 50 | Phase III |
DLBCL 80% BL 9% HG NOS 6% |
137 weeks | 47% | 38 weeks | 110 weeks | [29] |
| R-CHOP | 99 | 58% | 45 weeks | 139 weeks | ||||
| R-CDE | 74 | Pooled analysis, phase II |
DLBCL 72% BL 28% |
23 months | 70% | 59% | 64% | [34] |
| R-CHOP | 61 | Phase II |
DLBCL 71% BL 29% |
33 months | 77% | 69% | 75% | [35] |
| R-CHOP | 81 | Phase II | DLBCL 100% | 3 years | 69% | 77% | 56% | [36] |
| R-EPOCH | 110 | Phase II, randomized |
Arm A R-concurrent DLBCL 69% BL 31% Arm B R-sequential DLBCL 80% BL 20% |
30 months |
73% 55% |
66% 62% |
70% 67% |
[37] |
BL Burkitt’s lymphoma, CDE cyclophosphamide-doxorubicin-etoposide, CHOP cyclophosphamide-doxorubicin-vincristine-prednisolone, CR complete remission, DLBCL diffuse-large B cell lymphoma, EPOCH etoposide-prednisolone-vincristine-cyclophosphamide-doxorubicin, FFS failure-free survival, HG NOS high grade not otherwise specified, N/A not available, OS overall survival, PFS progression-free survival, R rituximab